TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 171 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $25,767,113 | -68.3% | 1,225,255 | -62.9% | 0.16% | -70.9% |
| Q3 2022 | $81,312,000 | +1.7% | 3,300,009 | 0.0% | 0.53% | +17.4% |
| Q2 2022 | $79,959,000 | -6.0% | 3,300,009 | 0.0% | 0.45% | -7.2% |
| Q1 2022 | $85,041,000 | +2.6% | 3,300,009 | +23.6% | 0.49% | +21.3% |
| Q4 2021 | $82,847,000 | +67.5% | 2,669,054 | +30.9% | 0.40% | +85.7% |
| Q3 2021 | $49,464,000 | +1713.9% | 2,039,772 | +991.3% | 0.22% | +1708.3% |
| Q2 2021 | $2,727,000 | -41.6% | 186,915 | 0.0% | 0.01% | -40.0% |
| Q1 2021 | $4,667,000 | – | 186,915 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 1,028,875 | $25,351,000 | 8.34% |
| GREAT POINT PARTNERS LLC | 966,108 | $23,805,000 | 5.73% |
| Deep Track Capital, LP | 4,000,000 | $98,560,000 | 4.51% |
| RA Capital Management | 4,922,941 | $121,301,000 | 2.59% |
| ARMISTICE CAPITAL, LLC | 5,836,000 | $143,799,000 | 2.49% |
| Kynam Capital Management, LP | 416,729 | $10,268,000 | 2.16% |
| MPM BioImpact LLC | 276,460 | $6,812,000 | 1.61% |
| HighVista Strategies LLC | 110,698 | $2,728,000 | 1.56% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 186,019 | $4,582,000 | 1.47% |
| SECTORAL ASSET MANAGEMENT INC | 249,700 | $6,153,000 | 1.21% |